Guggenheim Downgrades Intersect ENT to Neutral, Announces $28.25 Price Target
Guggenheim analyst Christopher Pasquale downgrades Intersect ENT (NASDAQ:XENT) from Buy to Neutral and announces $28.25 price target.
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 175 companies set new 52-week highs.
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise…
Intersect ENT: Q2 Earnings Insights
Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q2 results.
Quarterly Results
Earnings per share increased 24.62% year over year to ($0.49), which missed the estimate of ($0.43).
Intersect ENT Q2 Adj. EPS $(0.49) Misses $(0.43) Estimate, Sales $27.30M Miss $28.02M Estimate
Intersect ENT (NASDAQ:XENT) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.43) by 13.95 percent. This is a 24.62 percent increase over losses of $(0.65) per share from
Earnings Scheduled For August 6, 2021
Companies Reporting Before The Bell
• Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
Intersect ENT Inc (NASDAQ:XENT) expects Q2 sales of approximately $27.3 million, slightly below the consensus estimate of $28.02 million. Record…